Bristol Myers Squibb (BMY) Interest & Investment Income (2009 - 2013)
Bristol Myers Squibb (BMY) posted quarterly Interest & Investment Income of $25.0 million for Q1 2013, down 30.56% YoY from $36.0 million in Q1 2012, and down 30.56% sequentially from $36.0 million in Q1 2012.
Bristol Myers Squibb (BMY) Interest & Investment Income (2009 - 2013) Analysis & Trends
Bristol Myers Squibb has disclosed Interest & Investment Income across 3 years of filings, most recently posting $25.0 million for Q1 2013.
- In Q1 2013, Interest & Investment Income fell 30.56% year-over-year to $25.0 million; the TTM figure through Dec 2009 stood at $220.0 million (changed N/A YoY), while the FY2012 annual figure was $106.0 million, up 16.48% from the prior year.
- Interest & Investment Income retreated to $25.0 million in Q1 2013, from $36.0 million in the prior quarter.
- Over the last five years, Interest & Investment Income for BMY reached as high as $220.0 million in Q4 2009 and fell as low as $25.0 million in Q1 2013.
- The 3-year median for Interest & Investment Income is $36.0 million (2012), against an average of $93.7 million.
- The widest YoY moves for Interest & Investment Income: up 30.56% in 2013, down 30.56% in 2013.
- A 3-year view of Interest & Investment Income shows it stood at $220.0 million in 2009, then sank by 83.64% to $36.0 million in 2012, then tumbled by 30.56% to $25.0 million in 2013.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $25.0 million, $36.0 million, and $220.0 million for Q1 2013, Q1 2012, and Q4 2009 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 229.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -645.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 73.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 25.00 Mn |
| Mar 31, 2012 | 36.00 Mn |
| Dec 31, 2009 | 220.00 Mn |